Esperion Therapeutics, Inc. Reports Second Quarter Financial Results and Provides Corporate Update
8/12/2013 6:53:32 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided a corporate update and reported its financial results for the second quarter ended June 30, 2013.
Help employers find you! Check out all the jobs and post your resume.